Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Financing Activities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Cash from Financing Activities data on record, last reported at -$402000.0 in Q2 2025.

  • For Q2 2025, Cash from Financing Activities rose 34.53% year-over-year to -$402000.0; the TTM value through May 2025 reached $6.4 million, down 14.45%, while the annual FY2025 figure was $6.4 million, 14.45% down from the prior year.
  • Cash from Financing Activities reached -$402000.0 in Q2 2025 per LFCR's latest filing, up from -$6.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $24.6 million in Q2 2023 and bottomed at -$47.1 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $843833.3, with a median of $3.4 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: tumbled 506.36% in 2022, then soared 611.23% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $9.9 million in 2021, then decreased by 10.82% to $8.8 million in 2022, then crashed by 127.79% to -$2.4 million in 2023, then skyrocketed by 611.23% to $12.5 million in 2024, then plummeted by 103.21% to -$402000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$402000.0 in Q2 2025, -$6.8 million in Q1 2025, and $12.5 million in Q4 2024.